FDA timelines dictate your launch window, clinical evidence requirements shape your sales cycle, and reimbursement complexity determines your business model. You need a growth strategy built around those realities, not one borrowed from a SaaS playbook and bolted on after the fact.
The Problem
FDA timelines create unpredictable growth windows
Your commercial team can't plan hiring, channel investment, or territory expansion when a 510(k) or PMA timeline shifts by a quarter or two. Every delay cascades into missed revenue targets and pre-launch awareness spend that expires before clearance lands. Companies that start commercial work too late scramble post-clearance for six months; companies that start too early burn cash waiting on a date nobody can guarantee.
Clinical evidence requirements slow market adoption
Hospital procurement committees and physician champions want outcomes data before they'll consider your device, and building that evidence takes time, budget, and relationships with KOLs who are already stretched thin. Most medtech startups treat clinical evidence as a regulatory checkbox instead of the commercial asset it actually is. The companies that grow fastest build clinical and commercial strategy in parallel, not in sequence.
Reimbursement complexity affects business model viability
Your device might work clinically and still fail commercially if payers won't cover it. CPT code coverage, prior authorization requirements, and payer mix that varies by state make pricing and market-entry decisions genuinely hard to get right on the first try. Getting reimbursement wrong doesn't just slow growth – it breaks unit economics and makes every subsequent customer more expensive to acquire than the last.
Hospital procurement cycles outlast your cash runway
Selling into health systems means navigating value analysis committees, group purchasing organizations, and IT integration requirements that stretch sales cycles to 12-18 months. Most medtech growth models underestimate the time and headcount required to move from first meeting to signed contract. Add physician champion turnover and fiscal-year budget timing, and you have a sales process that punishes companies without a disciplined pipeline approach.
How We Help
We build growth strategies for medtech companies around the regulatory, clinical, and reimbursement realities that make this industry different from every other vertical we work in. No generic playbooks, no SaaS growth frameworks applied to a 510(k) product with the labels swapped out.
The engagement starts with a growth infrastructure assessment. We map your regulatory timeline, clinical evidence portfolio, reimbursement landscape, and existing commercial capabilities against your revenue targets. That tells us where the real gaps are and which ones matter most given your stage and runway – not a generic maturity score, a prioritized list.
From there we build a regulatory-aligned growth roadmap: commercial activities that create value before FDA clearance instead of waiting for it. KOL relationship development, health economics positioning, early payer conversations, and market shaping with target hospital systems. The goal is to compress time-to-revenue after clearance by doing everything legally permissible before it.
We treat clinical evidence as a commercial strategy, not just a regulatory requirement. We work with your clinical team to identify which data points procurement committees actually weigh and package outcomes data into materials that shorten the sales cycle instead of just satisfying a submission checklist.
On reimbursement, we build market-entry models around payer coverage variability – CPT code strategy, health economics value propositions, and geographic sequencing based on which regions have favorable coverage today, not two years ago.
What makes this different: we operate as embedded growth operators, not outside consultants. We own growth targets alongside your team and make resource allocation calls with you, not just for you. The fractional model gives you senior medtech growth expertise without the overhead of a full-time VP of Commercial, and the 90-day sprint structure means you see measurable progress at every phase instead of a strategy deck at the end.
We build measurement into the engagement from day one – baseline metrics before we touch anything, monthly reporting on what's working and what needs to change, and no vanity metrics. Only indicators that connect to pipeline and revenue.
What we deliver
- Regulatory-aligned growth roadmap that sequences commercial activities around FDA milestones
- Clinical evidence commercialization framework that translates outcomes data into sales acceleration
- Reimbursement-optimized market entry strategy with geographic and payer prioritization
- Hospital procurement playbook covering value analysis committees, GPO strategy, and physician champion development
The medtech companies that grow fastest treat clinical evidence as a commercial strategy, not a regulatory checkbox.
Our Methodology
Our methodology runs a 90-day sprint adapted to regulated markets. In the first 30 days we embed with your team to audit commercial infrastructure, map your regulatory timeline, evaluate your clinical evidence portfolio, and assess reimbursement readiness – reviewing KOL relationships, pipeline data, and existing health economics materials firsthand rather than taking a deck at face value.
Days 30-60 focus on strategy development and early execution. We build a growth roadmap aligned to your FDA timeline and start implementing the highest-impact changes first, including measurement frameworks tied to real commercial metrics: pipeline velocity, KOL engagement quality, and payer coverage progress.
Days 60-90 shift to full execution. Growth systems are running, the team is aligned, and we're optimizing based on live data instead of assumptions. By the end of the sprint you have a commercial growth engine with clear ownership and a roadmap that holds whether we stay on or not.
How We Work
Growth strategy engagements begin with a 2-3 week diagnostic. We audit your commercial infrastructure, map the competitive landscape, review your clinical evidence portfolio, and benchmark go-to-market capabilities against companies at a similar regulatory stage.
Weeks 3-8 focus on strategy development and initial execution. We build a regulatory-aligned growth roadmap with clear milestones and launch early initiatives around KOL development, payer engagement, or hospital system targeting. Weekly syncs and bi-weekly written reports keep the team aligned without adding meeting overhead.
From month 3 onward we're in optimization mode – scaling what's working, cutting what isn't, and pressure-testing assumptions against real market feedback. Monthly strategy reviews with leadership keep growth targets aligned with regulatory progress instead of drifting apart from it.
Typical engagements run 4-6 months with a dedicated growth lead embedded in your operating rhythm – attending leadership meetings, coordinating with clinical and regulatory teams, and making resource allocation decisions alongside your executives, not just advising from the sidelines.
- Regulatory-aligned growth strategy
- Clinical evidence commercialization framework
- Reimbursement-optimized market entry
If your healthcare & medtech company needs growth strategy leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How do you build a growth strategy around unpredictable FDA timelines?
We sequence commercial activities into pre-clearance and post-clearance phases. Before clearance, we focus on KOL development, health economics positioning, early payer conversations, and market shaping with target hospital systems. When clearance arrives, you're not starting from zero – the commercial engine is already warm and time-to-revenue compresses significantly.
What role does clinical evidence play in your growth strategy?
Clinical evidence is the single most important commercial asset in medtech. We work with your clinical team to identify which outcomes data matters most to hospital procurement committees and physician decision-makers, then build that evidence into sales materials, KOL talking points, and payer value propositions. Companies that treat evidence as only a regulatory requirement leave their best sales tool on the shelf.
How do you approach reimbursement as part of market entry?
Reimbursement determines whether your growth model works or breaks. We map CPT code coverage across target payers and geographies, build health economics value propositions for payer audiences, and prioritize market entry in regions with favorable reimbursement dynamics today. We also help structure pilot programs with hospital systems that generate the utilization data payers need to expand coverage.
How long does a medtech growth strategy engagement take?
Diagnostic and strategy development take 6-8 weeks. Implementation and optimization run 3-6 months depending on your regulatory stage and commercial complexity. The 90-day sprint gives you a functioning growth system with clear ownership and metrics, and most clients extend into a second sprint as they approach or pass a regulatory milestone.
How is this different from hiring a healthcare marketing agency?
Agencies execute campaigns within defined channels. Growth strategy determines which markets to enter, how to structure your commercial model around reimbursement constraints, and how to turn clinical evidence into pipeline acceleration. We work at the strategic layer and make resource allocation decisions alongside your leadership team – agencies are often part of the execution plan we build, not a substitute for the strategy itself.
What does this cost compared to hiring a full-time VP of Commercial?
Growth strategy engagements typically run $15K-$30K per month depending on scope. A full-time VP of Commercial in medtech costs $250K-$400K fully loaded, takes 4-6 months to recruit in a specialized talent market, and carries real hiring risk if the fit is wrong. The fractional model gives you experienced medtech growth leadership immediately, with flexibility to scale as milestones evolve.
